Abstract
CD20 protein is expressed on the surface membrane of pre-B lymphocytes and mature B lymphocytes. The protein is located in the B-cell membrane, with 44 amino acids exposed in the extracellular space. Rituximab is a chimeric anti-CD20 antibody whose variable (antigen-binding) region was derived from a mouse antibody so that it has high affinity for CD20. The binding of rituximab to the CD20 antigen interferes with the activation and differentiation of B cells.1 Hematopoietic stem cells, pro-B lymphocytes, and plasma cells do not express CD20. This distribution permits the specific elimination of B cells without preventing the regeneration of B . . .
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
